Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. / Gasbjerg, Lærke S; Helsted, Mads M; Hartmann, Bolette; Jensen, Mette H; Gabe, Maria B N; Sparre-Ulrich, Alexander H; Veedfald, Simon; Stensen, Signe; Lanng, Amalie R; Bergmann, Natasha C; Christensen, Mikkel B; Vilsbøll, Tina; Holst, Jens J; Rosenkilde, Mette M; Knop, Filip K.

I: Diabetes, Bind 68, Nr. 3, 2019, s. 906-917.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Gasbjerg, LS, Helsted, MM, Hartmann, B, Jensen, MH, Gabe, MBN, Sparre-Ulrich, AH, Veedfald, S, Stensen, S, Lanng, AR, Bergmann, NC, Christensen, MB, Vilsbøll, T, Holst, JJ, Rosenkilde, MM & Knop, FK 2019, 'Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals', Diabetes, bind 68, nr. 3, s. 906-917. https://doi.org/10.2337/db18-1123

APA

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., ... Knop, F. K. (2019). Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes, 68(3), 906-917. https://doi.org/10.2337/db18-1123

Vancouver

Gasbjerg LS, Helsted MM, Hartmann B, Jensen MH, Gabe MBN, Sparre-Ulrich AH o.a. Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes. 2019;68(3):906-917. https://doi.org/10.2337/db18-1123

Author

Gasbjerg, Lærke S ; Helsted, Mads M ; Hartmann, Bolette ; Jensen, Mette H ; Gabe, Maria B N ; Sparre-Ulrich, Alexander H ; Veedfald, Simon ; Stensen, Signe ; Lanng, Amalie R ; Bergmann, Natasha C ; Christensen, Mikkel B ; Vilsbøll, Tina ; Holst, Jens J ; Rosenkilde, Mette M ; Knop, Filip K. / Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. I: Diabetes. 2019 ; Bind 68, Nr. 3. s. 906-917.

Bibtex

@article{45c3c2e1d16b4d3aa0dde6ba9f360704,
title = "Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals",
abstract = "The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted postprandially and contribute importantly to postprandial glucose tolerance. Here, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and gluco-regulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH2During four-hour oral glucose tolerance tests (75 g) combined with an ad libitum meal test, 18 healthy men received on four separate days in randomized, double-blinded order intravenous infusions of A) GIP(3-30)NH2 (800 pmol/kg/min)+exendin(9-39)NH2 (0-20 min: 1,000 pmol/kg/min; 20-240 min: 450 pmol/kg/min), B) GIP(3-30)NH2, C) exendin(9-39)NH2, and D) saline, respectively.Glucose excursions were significantly higher during A than during B, C, and D while glucose excursions during B were higher than during C and D. Insulin secretion (assessed by C-peptide:glucose ratio) was reduced by 37±16{\%} (A), 30±17{\%} (B), and 8.6±16{\%} (C) compared to D (mean±standard deviation). A and C resulted in higher glucagon levels, and faster gastric emptying.In conclusion, endogenous GIP affects postprandial plasma glucose excursions and insulin secretion more than endogenous GLP-1, but the hormones contribute additively to postprandial glucose regulation in healthy individuals.Trial no. (Clinicaltrials.gov): NCT03133741.",
author = "Gasbjerg, {L{\ae}rke S} and Helsted, {Mads M} and Bolette Hartmann and Jensen, {Mette H} and Gabe, {Maria B N} and Sparre-Ulrich, {Alexander H} and Simon Veedfald and Signe Stensen and Lanng, {Amalie R} and Bergmann, {Natasha C} and Christensen, {Mikkel B} and Tina Vilsb{\o}ll and Holst, {Jens J} and Rosenkilde, {Mette M} and Knop, {Filip K}",
note = "{\circledC} 2019 by the American Diabetes Association.",
year = "2019",
doi = "10.2337/db18-1123",
language = "English",
volume = "68",
pages = "906--917",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association",
number = "3",

}

RIS

TY - JOUR

T1 - Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals

AU - Gasbjerg, Lærke S

AU - Helsted, Mads M

AU - Hartmann, Bolette

AU - Jensen, Mette H

AU - Gabe, Maria B N

AU - Sparre-Ulrich, Alexander H

AU - Veedfald, Simon

AU - Stensen, Signe

AU - Lanng, Amalie R

AU - Bergmann, Natasha C

AU - Christensen, Mikkel B

AU - Vilsbøll, Tina

AU - Holst, Jens J

AU - Rosenkilde, Mette M

AU - Knop, Filip K

N1 - © 2019 by the American Diabetes Association.

PY - 2019

Y1 - 2019

N2 - The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted postprandially and contribute importantly to postprandial glucose tolerance. Here, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and gluco-regulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH2During four-hour oral glucose tolerance tests (75 g) combined with an ad libitum meal test, 18 healthy men received on four separate days in randomized, double-blinded order intravenous infusions of A) GIP(3-30)NH2 (800 pmol/kg/min)+exendin(9-39)NH2 (0-20 min: 1,000 pmol/kg/min; 20-240 min: 450 pmol/kg/min), B) GIP(3-30)NH2, C) exendin(9-39)NH2, and D) saline, respectively.Glucose excursions were significantly higher during A than during B, C, and D while glucose excursions during B were higher than during C and D. Insulin secretion (assessed by C-peptide:glucose ratio) was reduced by 37±16% (A), 30±17% (B), and 8.6±16% (C) compared to D (mean±standard deviation). A and C resulted in higher glucagon levels, and faster gastric emptying.In conclusion, endogenous GIP affects postprandial plasma glucose excursions and insulin secretion more than endogenous GLP-1, but the hormones contribute additively to postprandial glucose regulation in healthy individuals.Trial no. (Clinicaltrials.gov): NCT03133741.

AB - The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted postprandially and contribute importantly to postprandial glucose tolerance. Here, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and gluco-regulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH2During four-hour oral glucose tolerance tests (75 g) combined with an ad libitum meal test, 18 healthy men received on four separate days in randomized, double-blinded order intravenous infusions of A) GIP(3-30)NH2 (800 pmol/kg/min)+exendin(9-39)NH2 (0-20 min: 1,000 pmol/kg/min; 20-240 min: 450 pmol/kg/min), B) GIP(3-30)NH2, C) exendin(9-39)NH2, and D) saline, respectively.Glucose excursions were significantly higher during A than during B, C, and D while glucose excursions during B were higher than during C and D. Insulin secretion (assessed by C-peptide:glucose ratio) was reduced by 37±16% (A), 30±17% (B), and 8.6±16% (C) compared to D (mean±standard deviation). A and C resulted in higher glucagon levels, and faster gastric emptying.In conclusion, endogenous GIP affects postprandial plasma glucose excursions and insulin secretion more than endogenous GLP-1, but the hormones contribute additively to postprandial glucose regulation in healthy individuals.Trial no. (Clinicaltrials.gov): NCT03133741.

U2 - 10.2337/db18-1123

DO - 10.2337/db18-1123

M3 - Journal article

C2 - 30626611

VL - 68

SP - 906

EP - 917

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 3

ER -

ID: 214748990